| Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases RS Muraoka, N Dumont, CA Ritter, TC Dugger, DM Brantley, J Chen, ... The Journal of clinical investigation 109 (12), 1551-1559, 2002 | 679 | 2002 |
| TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer NE Bhola, JM Balko, TC Dugger, MG Kuba, V Sánchez, M Sanders, ... The Journal of clinical investigation 123 (3), 1348-1358, 2013 | 638 | 2013 |
| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... Cancer discovery 4 (2), 232-245, 2014 | 549 | 2014 |
| RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune … S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ... Clinical Cancer Research 22 (6), 1499-1509, 2016 | 539 | 2016 |
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase JT Garrett, MG Olivares, C Rinehart, ND Granja-Ingram, V Sánchez, ... Proceedings of the National Academy of Sciences 108 (12), 5021-5026, 2011 | 518 | 2011 |
| mTORC1 and mTORC2 in cancer and the tumor microenvironment LC Kim, RS Cook, J Chen Oncogene 36 (16), 2191-2201, 2017 | 422 | 2017 |
| MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors AB Turke, Y Song, C Costa, R Cook, CL Arteaga, JM Asara, JA Engelman Cancer research 72 (13), 3228-3237, 2012 | 406 | 2012 |
| Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo DM Brantley, N Cheng, EJ Thompson, Q Lin, RA Brekken, PE Thorpe, ... Oncogene 21 (46), 7011-7026, 2002 | 406 | 2002 |
| Biological consequences of MHC-II expression by tumor cells in cancer ML Axelrod, RS Cook, DB Johnson, JM Balko Clinical cancer research 25 (8), 2392-2402, 2019 | 364 | 2019 |
| Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP-and HGF-mediated signaling networks N Cheng, NA Bhowmick, A Chytil, AE Gorksa, KA Brown, R Muraoka, ... Oncogene 24 (32), 5053-5068, 2005 | 343 | 2005 |
| Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer AJ Walsh, RS Cook, HC Manning, DJ Hicks, A Lafontant, CL Arteaga, ... Cancer research 73 (20), 6164-6174, 2013 | 328 | 2013 |
| The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling DM Brantley-Sieders, G Zhuang, D Hicks, WB Fang, Y Hwang, JMM Cates, ... The Journal of clinical investigation 118 (1), 64-78, 2008 | 321 | 2008 |
| Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance JM Balko, RS Cook, DB Vaught, MG Kuba, TW Miller, NE Bhola, ... Nature medicine 18 (7), 1052-1059, 2012 | 312 | 2012 |
| Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer AJ Walsh, RS Cook, ME Sanders, L Aurisicchio, G Ciliberto, CL Arteaga, ... Cancer research 74 (18), 5184-5194, 2014 | 302 | 2014 |
| Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy G Zhuang, DM Brantley-Sieders, D Vaught, J Yu, L Xie, S Wells, ... Cancer research 70 (1), 299-308, 2010 | 271 | 2010 |
| Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor β1 RS Muraoka, Y Koh, LR Roebuck, ME Sanders, D Brantley-Sieders, ... Molecular and cellular biology, 2003 | 266 | 2003 |
| Dual role of transforming growth factor β in mammary tumorigenesis and metastatic progression RS Muraoka-Cook, N Dumont, CL Arteaga Clinical cancer research 11 (2), 937s-943s, 2005 | 220 | 2005 |
| The relationship between obesity and hypoferraemia in adults: a systematic review HL Cheng, C Bryant, R Cook, H O'connor, K Rooney, K Steinbeck obesity reviews 13 (2), 150-161, 2012 | 211 | 2012 |
| Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies AB Hanker, AD Pfefferle, JM Balko, MG Kuba, CD Young, V Sánchez, ... Proceedings of the National Academy of Sciences 110 (35), 14372-14377, 2013 | 203 | 2013 |
| Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer DN Edwards, VM Ngwa, AL Raybuck, S Wang, Y Hwang, LC Kim, SH Cho, ... The Journal of clinical investigation 131 (4), 2021 | 194 | 2021 |
Justin M. BalkoProfessor of Medicine, and Pathology, Microbiology, and Immunology, Vanderbilt University在 vumc.org 的电子邮件经过验证
